Policy Making

Showing 1388 articles
Business

AbCellera Biologics: A Tale of Two Valuations Amid Steep Share Decline

Shares of antibody discovery firm AbCellera Biologics plunged 16.8% last week, reigniting debate over its true worth. While a discounted cash flow model suggests deep undervaluation, its sky-high price-to-sales ratio paints a starkly different picture, leaving investors to navigate conflicting signals in a volatile biotech market.

Business

Fastly's AI-Driven Rally: Sustainable Momentum or Short-Lived Hype?

Fastly's stock has surged on the coattails of broader AI and edge computing optimism, but a closer look reveals a complex picture of short-term gains against longer-term struggles. As the market weighs future growth against persistent losses, investors are left questioning if the recent rally has legs.

Business

Dynatrace Stock Plunge: A Buying Opportunity or a Value Trap?

Dynatrace shares have tumbled over 34% in the past year, significantly underperforming the broader software sector. A deep dive into valuation metrics, including discounted cash flow and peer comparisons, suggests the stock may be trading at a substantial discount. We examine the numbers and the narrative shaping investor sentiment.